Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed -5.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Stock-based compensation changed +4.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.